Biogen says FDA extending review of hemophilia drug

(Reuters) - Biogen Idec Inc on Monday said the U.S. Food and Drug Administration will extend by three months its deadline for reviewing the company's experimental long-acting medicine for hemophilia.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/12/biogen-says-fda-extending-review-of_2.html